Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 13/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 12/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 10/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13003254 | 0.86 | MAPK14 (0.44) | MAPK9MAPK10MAPK8MAPK14MAPK1 | |
| SCHEMBL10273087 | 0.75 | MAPK14 (0.55) | MAPK9MAPK10MAPK8MAPK14MAPK1 | |
| SCHEMBL13937256 | 0.72 | MAPK14 (0.50) | MAPK10MAPK14 | |
| SCHEMBL765369 | 0.71 | MAPK14 (0.41) | MAPK14MAPK1OPRK1 | |
| SCHEMBL13003262 | 0.71 | MAPK14 (0.44) | MAPK9MAPK10MAPK8MAPK14 | |
| SCHEMBL753472 | 0.70 | RIPK3 (0.39) | MAPK14 | |
| SCHEMBL752215 | 0.69 | MAPK14 (0.47) | MAPK10MAPK14 | |
| SCHEMBL751894 | 0.69 | USP7 (0.38) | MAPK14 | |
| SCHEMBL752508 | 0.69 | RIPK3 (0.46) | MAPK14 | |
| SCHEMBL750843 | 0.67 | MAPK14 (0.42) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439174-B1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
| US-7473695-B2 | 4-imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-06 | — | — | US | disclosed |
| US-7473695-B2 | 4-imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | OR10J3, NR4A3, NR3C2 | MAPK9 2611/4885MAPK10 2070/4885MAPK8 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.